Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21813616rdf:typepubmed:Citationlld:pubmed
pubmed-article:21813616lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C0680220lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C0019764lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C0039215lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C0035668lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C1332700lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C1413221lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:21813616lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:21813616pubmed:issue19lld:pubmed
pubmed-article:21813616pubmed:dateCreated2011-9-12lld:pubmed
pubmed-article:21813616pubmed:abstractTextPercentages of activated T cells correlate with HIV-1 disease progression, but the underlying mechanisms are not fully understood. We hypothesized that HLA-DR(+) CD38(+) (DR(+) 38(+)) CD4(+) T cells produce the majority of HIV-1 due to elevated expression of CCR5 and CXCR4. In phytohemagglutinin (PHA)-stimulated CD8-depleted peripheral blood mononuclear cells (PBMC) infected with HIV-1 green fluorescent protein (GFP) reporter viruses, DR(-) 38(+) T cells constituted the majority of CCR5 (R5)-tropic (median, 62%) and CXCR4 (X4)-tropic HIV-1-producing cells (median, 61%), although cell surface CCR5 and CXCR4 were not elevated in this subset of cells. In lymph nodes from untreated individuals infected with R5-tropic HIV-1, percentages of CCR5(+) cells were elevated in DR(+) 38(+) CD4(+) T cells (median, 36.4%) compared to other CD4(+) T-cell subsets (median values of 5.7% for DR(-) 38(-) cells, 19.4% for DR(+) 38(-) cells, and 7.6% for DR(-) 38(+) cells; n = 18; P < 0.001). In sorted CD8(-) lymph node T cells, median HIV-1 RNA copies/10(5) cells was higher for DR(+) 38(+) cells (1.8 × 10(6)) than for DR(-) 38(-) (0.007 × 10(6)), DR(-) 38(+) (0.064 × 10(6)), and DR(+) 38(-) (0.18 × 10(6)) subsets (n = 8; P < 0.001 for all). After adjusting for percentages of subsets, a median of 87% of viral RNA was harbored by DR(+) 38(+) cells. Percentages of CCR5(+) CD4(+) T cells and concentrations of CCR5 molecules among subsets predicted HIV-1 RNA levels among CD8(-) DR/38 subsets (P < 0.001 for both). Median HIV-1 DNA copies/10(5) cells was higher in DR(+) 38(+) cells (5,360) than in the DR(-) 38(-) (906), DR(-) 38(+) (814), and DR(+) 38(-) (1,984) subsets (n = 7; P ? 0.031). Thus, DR(+) 38(+) CD4(+) T cells in lymph nodes have elevated CCR5 expression, are highly susceptible to infection with R5-tropic virus, and produce the majority of R5-tropic HIV-1. PBMC assays failed to recapitulate in vivo findings, suggesting limited utility. Strategies to reduce numbers of DR(+) 38(+) CD4(+) T cells may substantially inhibit HIV-1 replication.lld:pubmed
pubmed-article:21813616pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:languageenglld:pubmed
pubmed-article:21813616pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:citationSubsetIMlld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21813616pubmed:statusMEDLINElld:pubmed
pubmed-article:21813616pubmed:monthOctlld:pubmed
pubmed-article:21813616pubmed:issn1098-5514lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:LevyDavid NDNlld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:ConnickElizab...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:FolkvordJoy...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:CampbellThoma...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:LieYolandaYlld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:CoakleyEoinElld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:MawhinneySama...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:McCarterMarti...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:MeditzAmie...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:HaasMichelle...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:MelanderKelse...lld:pubmed
pubmed-article:21813616pubmed:authorpubmed-author:YoungRussRlld:pubmed
pubmed-article:21813616pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21813616pubmed:volume85lld:pubmed
pubmed-article:21813616pubmed:ownerNLMlld:pubmed
pubmed-article:21813616pubmed:authorsCompleteYlld:pubmed
pubmed-article:21813616pubmed:pagination10189-200lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:meshHeadingpubmed-meshheading:21813616...lld:pubmed
pubmed-article:21813616pubmed:year2011lld:pubmed
pubmed-article:21813616pubmed:articleTitleHLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.lld:pubmed
pubmed-article:21813616pubmed:affiliationDepartment of Medicine, University of Colorado Denver, Aurora, CO 80045, USA.lld:pubmed
pubmed-article:21813616pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21813616pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed